美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效及安全性观察

Clinical Efficacy and Safety of Metoprolol Combined with Trimetazidine in the Treatment of Coronary Heart Disease and Heart Failure

目的:研讨曲美他嗪联合美托洛尔治疗冠心病(CAD)伴心力衰竭(HF)的疗效。方法:将80例CAD伴HF患者随机分为研究组41例与对照组39例,对照组给予曲美他嗪,研究组给予美托洛尔联合曲美他嗪,治疗1月后对比两组治疗前后LVEF、HR、LVDD、CRP、Hcy、BNP及不良反应。结果:治疗前两组LVEF、HR、LVDD及CRP、Hcy、BNP差异无统计学意义(P>0.05);治疗后研究组HR、LVDD及CRP、Hcy、BNP低于对照组(P<0.05),LVEF高于对照组(P<0.05);两组不良反应率差异无统计学意义(P>0.05)。结论:曲美他嗪联合美托洛尔可改善CAD伴HF患者心功能及冠脉血液循环,减轻血管内皮细胞损伤。

Objective:To investigate the efficacy of trimetazidine combined with metoprolol in the treatment of coronary heart disease(CAD)with heart failure(HF).Methods:80 patients with CAD and HF were randomly divided into study group(41 cases)and control group(39 cases).The control group was given trimetazidine,and the study group was given metoprolol combined with trimetazidine.LVEF,HR,LVDD,CRP,Hcy,BNP and adverse reactions were compared between the two groups before and after treatment.Results:Before treatment,there was no significant difference in LVEF,HR,LVDD,CRP,Hcy and BNP between the two groups(P>0.05).After treatment,HR,LVDD,CRP,Hcy and BNP of the study group were lower than those of the control group(P<0.05),LVEF was higher than that of the control group(P<0.05).There was no significant difference in adverse reaction rate between the two groups(P>0.05).Conclusion:Trimetazidine combined with metoprolol can improve the cardiac function and coronary blood circulation of CAD patients with HF,and reduce the damage of vascular endothelial cells.